Navigation Links
Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma

younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. will co-promote VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventri
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:1/22/2015)... 2015  ResMed Inc. (NYSE: RMD ) today announced ... the quarter was $423.0 million, a 10 percent increase compared ... increase on a constant currency basis). Net income was $91.2 ... ended December 31, 2013. Diluted earnings per share for the ...
(Date:1/22/2015)... 22, 2015  Bio-Techne Corporation (NASDAQ: TECH ) ... member of the new Simple Plex platform through its ... represents the re-branding of the previously acquired CyPlex instrument ... is a transformative immunoassay technology which integrates an innovatively ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) ... Diagnostics Market by Product, Application, Technology, End User - ... , The infectious disease diagnostics market is ... $18,156.2 million by 2019 from $12,422.8 million in 2014. ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... Fla., Nov. 18 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: ... phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA(TM)) ... in Orlando, FL,(1,2) with ONSET/OFFSET study results being simultaneously ... The ONSET/OFFSET data showed that treatment with ...
... , MADISON, N.J., Nov. 18 Quest Diagnostics Incorporated (NYSE: ... and services, today announced that the Simplexa Influenza A H1N1 (2009) ... and is now available as a test kit for distribution to ... at MEDICA 2009, November 18 to 21, 2009, at the Dusseldorf ...
Cached Medicine Technology:Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the Body 2Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the Body 3Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the Body 42009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name 22009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name 32009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name 42009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name 5
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... January 22, 2015 Joan Lunden, award-winning ... speaker at the upcoming 32nd Annual Miami Breast ... Physicians’ Education Resource®, LLC (PER®) , shares that “a ... gone undetected if she had not followed up her ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Step into ... at the Science Museum of Virginia. Wicked Plants, the ... Wicked Plants unearths 75 poisonous, carnivorous and diabolical plants ... each room to uncover the biochemical, physical and neurological ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... Campaign for Cancer Prevention (CCP) began in,2007 with the ... care about preventing cancer. It has now,grown to a ... initiative on the social media,platform, Causes.com. Nearly five years ... Women,s,Hospital (BWH), a Harvard Medical School flagship teaching hospital, ...
... male breast cancer is low and most men do not even ... new research from the University of Leeds. Breast cancer ... diagnoses in women in the UK each year. However around 340 ... cancer each year and around 70 men will die. Funded ...
... WASHINGTON, Oct. 3In a feat of technology tweaking that ... University of California, Davis has transformed everyday iPhones into ... cost about as much as a typical app, the ... to perform detailed microscopy and spectroscopy. The team ...
... the University of Bristol, has found that children who are ... more filling. This finding, published (online ahead of print) in ... because it reveals one way in which children over-consume snack ... are at risk of obesity due to consumption of energy-rich ...
... HealthDay Reporter , FRIDAY, Sept. 30 (HealthDay News) ... effective as psychiatric drugs in reducing the agitation that ... suggests. In a three-month period, nursing home residents ... involving music, mime and humorous props showed a significant ...
... accepted for publication in The Endocrine Society,s Journal ... shift work at a young age is associated ... Previous studies have shown that long-term elevated cortisol ... and cardiovascular risk. Shift work, defined as ...
Cached Medicine News:Health News:Campaign for Cancer Prevention connects 6 million+ members on Facebook Causes to research at BWH 2Health News:Campaign for Cancer Prevention connects 6 million+ members on Facebook Causes to research at BWH 3Health News:Researchers call for more awareness of male breast cancer as cases rise 2Health News:Researchers call for more awareness of male breast cancer as cases rise 3Health News:Researchers transform iPhone into high-quality medical imaging device 2Health News:Researchers transform iPhone into high-quality medical imaging device 3Health News:Researchers transform iPhone into high-quality medical imaging device 4Health News:New study finds familiarity increases the fullness that children expect from snack foods 2Health News:Laughter Might Be Good Medicine for Alzheimer's Patients 2Health News:Laughter Might Be Good Medicine for Alzheimer's Patients 3
Can download data from your A&D balance directly to your PC saving time and reducing the chances of manually recording the wrong weighing data; 60 month warranty; automatic adjustable environment set...
... is a fully automated genetic analysis system. ... with a patented linear polyacrylamide (LPA) gel, ... voltage program, and analyzes the data. Software ... and even customize automated data assessment. All ...
Coated-Tube (CT) RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum...
... an 125I radioimmunoassay designed for,in ... quantitative,measurement of estradiol in serum, ... in girls,and gynecomastia in men, ... amenorrhea. It is,also intended for ...
Medicine Products: